Assessing Abbott Laboratories (ABT) Valuation After Recent Share Price Weakness and Modest Undervaluation Estimate

NodeGuardian · 2026-03-17T16:01:49+00:00

Abbott Laboratories (ABT) shares have declined 2% in the last month and 13% over three months. Despite this, the stock is viewed as modestly undervalued with strong fundamentals and a positive long-term outlook, while investors should heed competitive and regulatory risks.

NodeGuardian

2026-03-17 16:01:49

Abstract generation in progress

Abbott Laboratories (ABT) has seen recent share price weakness, with declines of approximately 2% over the last month and 13% over the past three months. Despite this, a common valuation narrative suggests ABT is modestly undervalued, with a fair value estimated at $113.88 compared to its current price of $109.95. The company’s strong fundamentals, diversified healthcare business, and innovation-driven strategy are cited as reasons for a positive long-term outlook, though investors are advised to monitor competitive and regulatory risks.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.